Mabwell(SH:688062)2022-10-25 16:00Financial Performance - The company's revenue for Q3 2022 was ¥9,369,817.81, representing a year-over-year increase of 138.65%[5] - The net profit attributable to shareholders for Q3 2022 was -¥269,140,668.32, with a cumulative net profit of -¥692,421,947.18 for the year-to-date[5] - The company reported a net loss of ¥692,443,802.24 for the third quarter of 2022, compared to a net loss of ¥516,785,354.81 in the same quarter of 2021[36] - The net profit attributable to the parent company was -692,421,947.18 CNY, compared to -514,677,543.83 CNY in the previous period, indicating a decline of approximately 34.5%[38] - The total comprehensive income attributable to the parent company was -686,548,898.54 CNY, compared to -514,892,058.85 CNY in the previous period, reflecting a decrease of about 33.3%[38] - The basic and diluted earnings per share for Q3 2022 were both -¥0.67[9] - The basic and diluted earnings per share were both -1.73 CNY, slightly worse than -1.72 CNY in the previous period[38] Research and Development - Research and development (R&D) expenses for Q3 2022 totaled ¥219,632,291.20, an increase of 54.71% compared to the same period last year[9] - R&D expenses accounted for 2,344.04% of revenue in Q3 2022, a decrease of 1,271.75 percentage points year-over-year[9] - The company plans to continue investing heavily in R&D and market expansion efforts[15] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥4,674,158,465.61, reflecting a 193.00% increase from the end of the previous year[9] - Total assets increased to ¥4,674,158,465.61 from ¥1,595,272,932.19, marking a rise of 193.5%[32] - Non-current assets totaled ¥1,738,655,425.89, up from ¥1,350,536,548.64, reflecting a growth of 28.7%[32] - Current liabilities rose to ¥376,505,738.52, compared to ¥270,413,111.77, an increase of 39.1%[32] - Non-current liabilities increased to ¥549,994,973.00 from ¥316,239,201.27, representing a growth of 73.8%[32] - Total liabilities reached ¥926,500,711.52, up from ¥586,652,313.04, indicating a rise of 57.9%[32] Cash Flow - The company reported a net cash flow from operating activities of -¥507,698,762.84 for the year-to-date[5] - The net cash flow from operating activities was -507,698,762.84 CNY, worsening from -273,217,072.76 CNY year-over-year[42] - Cash inflow from operating activities totaled 210,660,495.27 CNY, up from 148,466,934.72 CNY in the previous year, representing an increase of approximately 41.9%[42] - Cash outflow from operating activities increased to 718,359,258.11 CNY, compared to 421,684,007.48 CNY in the previous year, marking a rise of about 70.5%[42] - The net cash flow from investing activities was -463,962,377.75 CNY, a decline from 67,436,973.20 CNY in the previous year[45] - Cash inflow from financing activities was 3,620,363,660.33 CNY, significantly higher than 219,891,719.89 CNY in the previous year, indicating an increase of approximately 1,646.5%[45] - The net cash flow from financing activities was 3,589,758,174.71 CNY, compared to 152,716,637.57 CNY in the previous year, showing a substantial increase of about 2,252.5%[45] - The ending cash and cash equivalents balance was 2,715,179,589.74 CNY, up from 251,874,170.63 CNY in the previous year, reflecting a growth of approximately 976.5%[45] Market and Sales Performance - The company attributed the increase in revenue to higher technical service income from Shengsen Pharmaceutical Co., Ltd.[15] - The company achieved a product sales volume of over 13,000 units in the first month after the launch of the adalimumab injection, with a total of 6,925 units sold in Q3 2022 due to temporary production supply issues[24] - The company has initiated sales control measures in Q3 2022 due to short-term production supply issues, impacting overall sales performance[24] - As of September 30, 2022, the company had a total of 447 hospitals and 653 pharmacies covered, with 45 hospitals achieving procurement access[24] - The company's strategic partnerships and collaborations, such as with Junshi Biosciences for the development of adalimumab, are expected to drive future growth and market expansion[24] Equity and Shareholder Information - Shareholders' equity attributable to the company was ¥3,749,863,521.15 at the end of Q3 2022, up 270.98% from the previous year[9] - The company's equity attributable to shareholders amounted to ¥3,749,863,521.15, compared to ¥1,010,804,531.15, an increase of 270.5%[32]